RHHBY - Roche Holding AG

Other OTC - Other OTC Delayed Price. Currency in USD
30.595
+0.760 (+2.55%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close29.835
Open30.720
Bid0.000 x 0
Ask0.000 x 0
Day's Range30.550 - 30.850
52 Week Range26.300 - 32.420
Volume924,522
Avg. Volume995,344
Market Cap202.174B
Beta (3Y Monthly)0.44
PE Ratio (TTM)19.93
EPS (TTM)1.535
Earnings DateN/A
Forward Dividend & Yield1.08 (3.63%)
Ex-Dividend Date2018-03-15
1y Target Est33.70
Trade prices are not sourced from all markets
  • Biogen (BIIB) Q3 Earnings Coming Up: What's in the Cards?
    Zacks7 hours ago

    Biogen (BIIB) Q3 Earnings Coming Up: What's in the Cards?

    On the third-quarter call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance.

  • Business Wire12 hours ago

    FDA Approves Label Update for Genentech’s Rituxan (Rituximab) in Two Rare Forms of Vasculitis

    SOUTH SAN FRANCISCO, Calif.-- -- Rituxan label updated to include information for follow up treatment in adult patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis who have achieved disease control with induction treatment Rituxan in combination with glucocorticoids is the only FDA-approved therapy for these rare, potentially life-threatening blood vessel disorders Genentech, ...

  • FDA Accepts Application for AbbVie's Imbruvica in Specific Blood Cancers
    GuruFocus.comyesterday

    FDA Accepts Application for AbbVie's Imbruvica in Specific Blood Cancers

    AbbVie (ABBV) has seen its marketing application for its drug Imbruvica combined with Roche (RO.SW)'s Gazyva, accepted by the U.S. Food and Drug Administration for a priority review as treatment for adult patients affected with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). If the U.S. agency approves the marketing application, the combined therapy of AbbVie's Imbruvica and Roche's Gazyva will be the first treatment given for lymphocytic leukaemia or small lymphocytic lymphoma.

  • Puma Biotech (PBYI) Rides High on Robust Nerlynx Performance
    Zacksyesterday

    Puma Biotech (PBYI) Rides High on Robust Nerlynx Performance

    Puma Biotech (PBYI) focuses on improving sales of its flagship and the only approved product Nerlynx. The drug's label expansion programs also appear promising.

  • The Wall Street Journal2 days ago

    [$$] Roche Sales Buoyed by New Drugs

    AG (ROG.EB) said Wednesday that its nine-month group sales rose on year, buoyed by new drugs. The Basel, Switzerland-based company said its nine-month group sales rose to 42.08 billion Swiss francs ($42.55 billion) up from CHF39.43 billion the year before. In the pharmaceuticals division, sales rose to CHF32.70 billion, up from CHF30.63 billion the year before.

  • Benzinga3 days ago

    The Daily Biotech Pulse: Eiger's Lymphoedema Drug Study Fails, Roche's Sales Rise

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 16) Endo International PLC (NASDAQ: ENDP ) Krystal Biotech ...

  • Beset by copies, Roche gets sales boost from China
    Reuters3 days ago

    Beset by copies, Roche gets sales boost from China

    Roche's (ROG.S) third-quarter revenue beat analysts' forecasts as new drugs such as Ocrevus for multiple sclerosis picked up pace and as China bought more of older medicines whose sales are dropping elsewhere following patent expiries. Third-quarter sales rose 7 percent to 13.97 billion Swiss francs (£10.7 billion), the Swiss drugmaker said on Wednesday, compared with analysts' average forecast of 13.8 billion francs in a Reuters poll. The company is also getting increasing support from its expansion in China, where sales of Avastin, Rituxan and Herceptin are on the rise and where regulators in August gave quick approval to one of Roche's newest medicines, Alecensa, for a tough-to-treat lung cancer mutation.

  • The Wall Street Journal3 days ago

    [$$] European Corporate News Roundup

    Trading updates from a number of European companies, including Danone, Pearson and Roche made the headlines on a busy day of corporate news in the region.

  • Reuters3 days ago

    Beset by copies, Roche gets sales boost from China

    Roche's third-quarter revenue beat analysts' forecasts as new drugs such as Ocrevus for multiple sclerosis picked up pace and as China bought more of older medicines whose sales are dropping elsewhere following patent expiries. Third-quarter sales rose 7 percent to 13.97 billion Swiss francs ($14.10 billion), the Swiss drugmaker said on Wednesday, compared with analysts' average forecast of 13.8 billion francs in a Reuters poll. The company is also getting increasing support from its expansion in China, where sales of Avastin, Rituxan and Herceptin are on the rise and where regulators in August gave quick approval to one of Roche's newest medicines, Alecensa, for a tough-to-treat lung cancer mutation.

  • Roche Announces Positive Data on Breast Cancer Drug Kadcyla
    Zacks4 days ago

    Roche Announces Positive Data on Breast Cancer Drug Kadcyla

    Roche's (RHHBY) breast cancer drug Kadcyla, in a late-stage study in patients suffering from HER2-positive eBCmet, met its goal.

  • PR Newswire5 days ago

    SQZ Biotech Expands Cell Therapy Partnership with Roche to Develop Antigen Presenting Cells for Immune-Oncology

    - Collaboration combines SQZ Biotech's novel cell therapy platform with Roche's cancer immunotherapy expertise - SQZ to receive up to $125 million in upfront and near-term milestone payments WATERTOWN, ...

  • GlobeNewswire5 days ago

    Roche's Kadcyla reduced the risk of disease recurring in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment

    Phase III KATHERINE study shows Kadcyla significantly improved invasive disease-free survival compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant ...

  • Business Wire5 days ago

    Genentech’s Kadcyla Reduced the Risk of Disease Recurring in People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment

    OTCQX: RHHBY), today announced the Phase III KATHERINE study met its primary endpoint, showing Kadcyla® (ado-trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival, iDFS) compared to Herceptin® (trastuzumab) as an adjuvant (after surgery) treatment in people with HER2-positive early breast cancer (EBC) who have residual disease (pathological invasive residual disease in the breast and/or axillary nodes) present following neoadjuvant (before surgery) treatment. The safety profile of Kadcyla in the KATHERINE study was consistent with previous clinical trials and no new safety signals were identified.

  • J&J (JNJ) Gets FDA Approval for Xarelto Label Expansion
    Zacks8 days ago

    J&J (JNJ) Gets FDA Approval for Xarelto Label Expansion

    Johnson & Johnson's (JNJ) Xarelto gets FDA approval for reducing risk of major cardiovascular events in chronic coronary or peripheral artery disease patients.

  • Benzinga8 days ago

    OTCQX Vs OTCQB Vs Pink: Understanding OTC Markets' Different Tiers

    Over the past 11 years, OTC Markets Group, operator of the over the counter equities markets, has organized this market into a tiered system based on the quality and timeliness of information a company has disclosed. The goal of organizing by tiers, according to Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group, was to help investors better understand the array of companies that trade here and the corresponding risks.

  • Teva Gets FDA Committee Nod for Rituxan Biosimilar Filing
    Zacks8 days ago

    Teva Gets FDA Committee Nod for Rituxan Biosimilar Filing

    Teva (TEVA) and partner Celltrion gets unanimous vote from an FDA advisory committee recommending approval of CT-P10, their proposed biosimilar to Roche's Rituxan.

  • Reuters9 days ago

    U.S. FDA panel backs Celltrion copycat of Roche blood cancer drug

    The tussles in the biosimilars market are a growing focus for investors, with soaring valuations for some pioneers in the field, including Celltrion, and worries about the long-term sales threat to makers of the original drugs such as Roche and AbbVie (ABBV.N). The vote comes after FDA staff reviewers https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM622649.pdf said Celltrion's biosimilar, CT-P10, was highly similar to Rituxan.

  • Reuters9 days ago

    UPDATE 1-U.S. FDA panel backs Celltrion copycat of Roche blood cancer drug

    Celltrion Inc's biosimilar of Roche Holding AG's blockbuster cancer drug, Rituxan, on Wednesday won unanimous backing from an advisory panel to the U.S. Food and Drug Administration. The tussles in the biosimilars market are a growing focus for investors, with soaring valuations for some pioneers in the field, including Celltrion, and worries about the long-term sales threat to makers of the original drugs such as Roche and AbbVie. The vote comes after FDA staff reviewers https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM622649.pdf said Celltrion's biosimilar, CT-P10, was highly similar to Rituxan.

  • Roche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus
    Zacks9 days ago

    Roche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus

    Roche's (RHHBY) MS drug Ocrevus lowers disability progression over five years in relapsing/primary progressive multiple sclerosis with an early initiation of treatment.

  • The Wall Street Journal10 days ago

    [$$] Ionis, Roche Reach New Collaboration Agreement

    AG in a deal that could be worth up to $760 million for Ionis. As part of the deal to develop a drug called IONIS-FB-L(Rx) for the treatment of a wide range of diseases, Ionis will get a $75 million upfront payment and will then be eligible to receive up to $684 million in development, regulatory and sales milestone payments and license fees. Ionis is responsible for conducting a Phase 2 study, slated to begin in early 2019, in patients suffering from age-related macular degeneration -- the leading cause of blindness in the U.S. and developed countries -- and exploring the drug in a rare severe renal indication.

  • Business Wire10 days ago

    OCREVUS (Ocrelizumab) Data Show Early Initiation of Treatment Reduces Disability Progression Over Five Years in Relapsing and Primary Progressive Multiple Sclerosis

    OTCQX: RHHBY), announced today that new OCREVUS® (ocrelizumab) data will be presented at the 34th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) from October 10-12 in Berlin, Germany. Five-year data from the Phase III open-label extension studies of OPERA I, OPERA II and ORATORIO show OCREVUS efficacy is maintained on key measures of disease activity and that people treated earlier with OCREVUS had superior disability progression outcomes compared with RMS patients who switched from interferon beta-1α or PPMS patients who switched from placebo. The new data presented at ECTRIMS demonstrate that OCREVUS’ efficacy continued over five years in relapsing and primary progressive MS, and notably, include the largest body of evidence for any medicine to significantly slow disability progression in primary progressive MS,” said Stephen Hauser, M.D., chair of the Scientific Steering Committee of the OPERA studies, professor of neurology at the University of California, San Francisco, and director of the UCSF Weill Institute for Neurosciences.

  • A Financial Overview of Ionis Pharmaceuticals in October
    Market Realist11 days ago

    A Financial Overview of Ionis Pharmaceuticals in October

    Ionis Pharmaceuticals generated second-quarter revenues of $118.0 million compared to $122.3 million in the second quarter of 2017, which reflected ~15.0% YoY (year-over-year) growth. In the first half, Ionis Pharmaceuticals reported revenues of $262.2 million, compared to $228.1 million in the first half of 2017.

  • An Update on Roche’s Neurology Business
    Market Realist11 days ago

    An Update on Roche’s Neurology Business

    Roche’s (RHHBY) Neurology segment generated net combined revenues of 1.4 billion Swiss francs in the first half of this year, reflecting 164.0% YoY (year-over-year) growth on a constant exchange basis. This segment consists of Ocrevus, Madopar, and other drugs. Ocrevus primarily pushed the revenue growth of Roche’s Neurology business.

  • Business Wire11 days ago

    Genentech to Present New Positive Data from Its Broad Cancer Immunotherapy Program and across a Wide Range of Cancers at the European Society for Medical Oncology (ESMO) 2018 Congress

    – First positive Phase III study results for a cancer immunotherapy combination in breast cancer, with Tecentriq® plus nab-paclitaxel –

  • AbbVie's Orilissa Gets Canadian Nod to Treat Endometriosis
    Zacks11 days ago

    AbbVie's Orilissa Gets Canadian Nod to Treat Endometriosis

    AbbVie (ABBV) and Neurocrine receive Canadian approval for Orilissa, for the treatment of moderate to severe pain associated with endometriosis.